Professor Amit Bahl

Professor Amit Bahl

Director of Oncology, Spire Healthcare, UK


I am a Consultant Clinical Oncologist at Bristol Cancer Institute, University Hospitals Bristol with a special interest in breast and urological cancers. I am the research lead for uro-oncology at Bristol Haematology and Oncology Centre. I have led and developed the prostate brachytherapy service at Bristol.

I am an internationally renowned expert on all aspects of prostate cancer treatment and can discuss the intricacies of the new modalities of treatment including IMRT, proton therapy, single modality HDR brachytherapy, enabling patients to come to an informed decision. I have been an expert adviser to NICE for the technology appraisal on new drugs and an external service reviewer at oncology departments elsewhere in the country.

Prior to my current roles, I became a member of the Royal College of Physicians (UK) and trained in clinical oncology, achieving the fellowship of the Royal College of Radiologists qualification. I have been awarded the fellowship of the Royal College of Physicians. I am a current member of the National Cancer Research Institute Clinical Studies Groups for bladder cancer and chair the penile cancer subgroup. I have been college tutor of the Royal College of Radiologists for 10 years and have supervised several MD theses in breast and prostate cancer research. I have previously been in the NCRI renal and prostate clinical studies group.

Since 2023, I am the Chairperson of the British Uro-oncology Group focussing on improving urological cancer outcomes across the UK. I am actively involved in research into breast, prostate, bladder and penile cancers and have more than 100 publications in these research areas and have several presentations at national and international meetings. In 2012, I was awarded the Cochrane Shanks Jalil Professorship by the Royal College of Radiologists, London and I am Visiting Professor to two international centres and at the University of West of England. I am currently holding research grants in excess of £3 million and am Chief Investigator for several multicentre trials focusing on new modalities of treatment in various cancers and am also leading the robotic brachytherapy project.


Treatment information

Some of the principal treatments carried out by Professor Amit Bahl at Spire include:


Clinical oncology

Get in touch

Important information about COVID-19 tests

COVID-19 testing or antibody tests are not available as a standalone service at Spire Bristol Hospital.


Marketing Information

Spire would like to provide you with marketing information about products and services offered by Spire and by selected third-party partners. If you do not consent for us to process your personal data for marketing activities, we will still be able to contact you about your enquiry.

We may contact you by email, SMS or phone about your enquiry. If we try to contact you by phone (mobile and/or landline) and you are not available, we may leave you a voicemail message. We may also use your details to contact you about patient surveys we use for improving our service or monitoring outcomes, which are not a form of marketing.

Submit my enquiry

Additional information

Bladder cancer
Breast cancer
Genito-urinary cancer
Kidney cancer
Prostate cancer

Dr Bahl is a national cancer consultant advisor for Spire and provides support to the National Oncology Pharmacists within the Governance team and support for the Spire iQemo Library of Chemotherapy treatment protocols for a payment of £40K per annum.